Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This trial evaluates the novel combination of docetaxel with imatinib as first or second line
therapy in advanced breast cancer with the aim of achieving higher effectiveness and
potentially reducing side effects.